Trial Profile
Biomarker-Panel Guided Maintenance Treatment With Cetuximab Monotherapy Versus Continuation After First Line Induction Therapy of Metastatic Colorectal Cancer (mCRC) : a Multicenter, Prospective, Randomized Controlled Trial
Status:
Not yet recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 06 Apr 2023
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Biomarker; Therapeutic Use
- 29 Apr 2021 Planned End Date changed from 1 Oct 2021 to 1 Oct 2022.
- 29 Apr 2021 Planned primary completion date changed from 1 Oct 2021 to 1 Oct 2022.
- 29 Apr 2021 Planned initiation date changed from 1 Nov 2020 to 1 Nov 2021.